Cargando…
Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial
No effective drug treatments are available for coronavirus disease 2019 (COVID-19). Host-directed therapies targeting the underlying aberrant immune responses leading to pulmonary tissue damage, death, or long-term functional disability in survivors require clinical evaluation. We performed a parall...
Autores principales: | Meng, Fanping, Xu, Ruonan, Wang, Siyu, Xu, Zhe, Zhang, Chao, Li, Yuanyuan, Yang, Tao, Shi, Lei, Fu, Junliang, Jiang, Tianjun, Huang, Lei, Zhao, Peng, Yuan, Xin, Fan, Xing, Zhang, Ji-Yuan, Song, Jinwen, Zhang, Dawei, Jiao, Yanmei, Liu, Limin, Zhou, Chunbao, Maeurer, Markus, Zumla, Alimuddin, Shi, Ming, Wang, Fu-Sheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450163/ https://www.ncbi.nlm.nih.gov/pubmed/32855385 http://dx.doi.org/10.1038/s41392-020-00286-5 |
Ejemplares similares
-
Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial
por: Shi, Lei, et al.
Publicado: (2021) -
Immunometabolism: new insights and lessons from antigen-directed cellular immune responses
por: Ramalho, Renata, et al.
Publicado: (2020) -
Immunometabolism and Pulmonary Infections: Implications for Protective Immune Responses and Host-Directed Therapies
por: Rao, Martin, et al.
Publicado: (2019) -
Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis
por: Zumla, Alimuddin, et al.
Publicado: (2016) -
Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial
por: Shi, Lei, et al.
Publicado: (2021)